Dfe Pharma Sustainability Profile
Dfe Pharma, headquartered in Germany, is a leading provider of excipients and pharmaceutical solutions, specialising in the development and manufacturing of high-quality products for the global pharmaceutical industry. Founded in 2015, the company has quickly established itself as a key player in the market, with a strong presence in Europe, North America, and Asia. Dfe Pharma's core offerings include a diverse range of excipients, such as binders, fillers, and disintegrants, which are essential for the formulation of solid dosage forms. What sets Dfe Pharma apart is its commitment to innovation and quality, ensuring that their products meet the stringent requirements of the pharmaceutical sector. With a focus on customer collaboration and tailored solutions, Dfe Pharma continues to enhance its market position, contributing to the success of its partners in the ever-evolving pharmaceutical landscape.
DitchCarbon Score
How does Dfe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dfe Pharma's score of 42 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dfe Pharma's reported carbon emissions
In 2024, DFE Pharma reported total Scope 3 emissions of approximately 815,000,000 kg CO2e. This marks a decrease from 2023, where emissions were about 917,000,000 kg CO2e, and from 2022, which recorded approximately 931,000,000 kg CO2e. The company has not disclosed any Scope 1 or Scope 2 emissions data for these years. DFE Pharma has set ambitious climate commitments, aiming for 100% carbon neutrality for Scope 1 and 2 emissions by 2030, with a baseline year of 2021. Additionally, the company has committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 42% and Scope 3 emissions by 25% within the same timeframe. Notably, DFE Pharma also targets a 30.3% reduction in Scope 3 emissions related to purchased goods and services, upstream transportation, and end-of-life treatment of sold products. These targets are part of a broader strategy to align with the Science Based Targets initiative (SBTi) and include commitments to no deforestation across primary deforestation-linked commodities by December 31, 2025. The emissions data and targets are cascaded from its parent company, DMV-Fonterra Excipients GmbH & Co. KG, reflecting a corporate family relationship that influences DFE Pharma's sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 6,566,000 | - | - | - | - |
| Scope 2 | 7,916,000 | - | - | - | - |
| Scope 3 | 989,802,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Dfe Pharma's Industry?
How Carbon Intensive is Dfe Pharma's Location?
Dfe Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dfe Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Frequently Asked Questions
Common questions about Dfe Pharma's sustainability data and climate commitments